Xiamen Spacegen Co., Ltd. (2025)

28/11/2025

With the rapid development of medical technology, genetic testing has become an indispensable tool in the diagnosis and treatment of gynecological tumors. Despite its significant value, the application of genetic testing faces numerous challenges:

1. Low detection rates: For instance, the detection rate of homologous recombination deficiency (HRD) in ovarian cancer is only 30%. This situation calls for enhanced patient awareness.
2. Technical standardization: Different detection methods, such as immunohistochemistry (IHC), next - generation sequencing (NGS), and polymerase chain reaction (PCR), require further standardization.
3. Cost and accessibility issues: Genetic testing is costly, and medical insurance coverage needs improvement.
4. Data interpretation: It should be combined with clinical and pathological features to avoid over - interpretation or misinterpretation.
5. Multi - disciplinary collaboration: Collaboration among teams from gynecological oncology, pathology, and genetic counseling needs to be strengthened. Enhanced communication can help develop individualized treatment plans.
6. Ethical and privacy concerns: Strict data protection mechanisms should be established to prevent the leakage of genetic data.

In the future, with the development of liquid biopsy, multi - omics integration, and artificial intelligence, genetic testing will offer more precise and convenient guidance for clinical decision - making.

26/11/2025

Low expression of HER2 in Breast Cancer? Ultra-low expression?

Human epidermal growth factor receptor 2 (HER2) is a significant driver gene for breast cancer and an important target for targeted therapy. Currently, the expression level is primarily detected using immunohistochemistry (IHC), with in situ hybridization (FISH) technology employed to supplement the assessment of gene amplification status. This status can be categorized into two groups: HER2-positive and HER2-negative. Traditional targeted therapy against HER2 has been based mainly on HER2 positivity, which means only about 10-20% of breast cancer patients could benefit from such therapy. However, with the introduction of new antibody-drug conjugates (ADCs), the reliance on HER2 overexpression or gene amplification for traditional targeted anti-HER2 therapy has been disrupted. The conventional approach to anti-HER2 therapy has been redefined, and low expression (HER2 low) and ultra-low expression (HER2 ultralow) have been established as independent therapeutic targets for breast cancer. This development not only paves a new path for targeted therapy for traditionally "HER2-negative" patients but also broadens the population that can benefit from anti-HER2 therapy.

25/11/2025

Ovarian cancer is the deadliest form of gynecological cancer. Despite the introduction of Bevacizumab, standard chemotherapy protocols have largely remained the same, and most patients experience a relapse within the first two years after diagnosis. However, clinical practice has shown that the clinical benefits of PARP inhibitors are rapidly transforming treatment options for many ovarian cancer patients. Although various combination therapies may improve the efficacy of PARP inhibitors and overcome resistance mechanisms, identifying the patients most likely to benefit is essential. Therefore, it is crucial to identify sufficient predictive biomarkers to aid in accurate patient selection.

21/11/2025

The National Comprehensive Cancer Network (NCCN) released the latest "Clinical Practice Guidelines for Non-Small Cell Lung Cancer (NSCLC) Version 1.2026" on November 6, 2025. Compared to the 8th edition from 2025, it has undergone several significant updates. The new version of the guideline has achieved a "disruptive" update in the field of biomarker testing—from the definition of terms to the scope of testing, from technical paths to clinical linkage, it has comprehensively propelled the precise treatment of lung cancer into a new era of "full-spectrum testing."
For patients, genetic testing is no longer an "optional add-on," but the "key first step" that determines the treatment direction and survival time. For clinicians, the guideline provides a standardized testing path, avoiding treatment delays caused by incomplete testing and inappropriate timing. With the deepening understanding of tumor biology, in the future, genetic testing will not only identify single mutations but also comprehensively assess the molecular characteristics of tumors, including co-mutation situations, tumor heterogeneity, and evolutionary mechanisms, etc. Multidisciplinary collaboration is particularly important in the precise diagnosis and treatment of lung cancer. Facing the increasingly complex and variable biological characteristics of tumors, a single treatment approach is no longer sufficient to meet the challenges. Therefore, future precise treatment will be a cross-disciplinary collaborative effort, forming a more comprehensive and precise treatment system.

31/10/2025

Ovarian endometrioid cancer (OEC) is an epithelial malignant tumor of the o***y that exhibits a pathological morphology similar to endometrioid cancer of the endometrium. Its incidence rate ranks second only to high-grade serous cancer of the o***y, accounting for approximately 10% of all epithelial malignant tumors of the o***y. Common molecular mutations in OEC include those of the CTNNB1 and PTEN genes, as well as microsatellite instability (MSI). Other observed mutations are dMMR or POLE (15%), HRD (19%), BRCA1/2 mutations (6%), and PIK3CA mutations (31%).

Despite differences in the proportion of TCGA molecular subtypes and pathological features between ovarian endometrioid cancer and endometrial endometrioid cancer, the prognostic value of TCGA molecular subtypes is similar in both cancers. The extension of endometrial molecular classification to ovarian endometrioid cancer represents not only a technical advancement but also a paradigm shift in diagnosis and treatment. It moves our focus from the "location of the tumor" to the "molecular characteristics of the tumor," and from "uniform treatment" to "personalized treatment." For patients with OEC, this translates to increased hope for survival: early-stage patients can avoid overtreatment, advanced-stage patients can find precise treatment options, and young patients can maintain their fertility. For clinicians, this means a clearer diagnostic and treatment pathway, with each treatment decision backed by "molecular evidence."

💡Click to read: http://sspacegen.com/newsinfo.aspx?newsID=480&CateID=109&wb=3

31/10/2025

When discussing melanoma, it is often referred to as the "king of skin cancers." It is highly deceptive in its early stages, challenging to treat in advanced stages, and the risk of recurrence looms like a sword of Damocles over patients' heads. Traditional monitoring methods, such as imaging exams, frequently fail to detect abnormalities until the tumor has progressed to a certain stage, potentially narrowing the window for effective treatment.

Nevertheless, the advent of "liquid biopsy" technology, which involves the detection of circulating tumor DNA (ctDNA), is revolutionizing the diagnosis and treatment of melanoma. For patients with melanoma, the importance of ctDNA detection is twofold: it is crucial for monitoring minimal residual disease (MRD) in the early postoperative period and for assessing treatment efficacy in advanced stages. "Recurrence" is the root of fear, but "early detection" is the key to conquering it. The advent of ctDNA detection has made it possible to "anticipate recurrence," "monitor therapeutic effects in real-time," and "accurately stratify risks," offering new hope to patients.

💡Click to read: http://sspacegen.com/newsinfo.aspx?newsID=479&CateID=109&wb=3

15/10/2025

On October 11, 2025, according to official information released by the National Medical Products Administration (NMPA), Sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate (ADC) independently developed by Kelun Biotech, has been granted approval for a new indication, offering an additional therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) in China. The newly approved indication is for the treatment of adult patients with locally advanced or metastatic NSCLC harboring epidermal growth factor receptor (EGFR) mutations who have experienced disease progression following prior therapy with EGFR tyrosine kinase inhibitors (EGFR-TKIs).

This is the third important indication approved by Sacituzumab in China after the back-line treatment for triple-negative breast cancer and specific non-small cell lung cancer, marking a further expansion of the application domain of this innovative domestic ADC drug in tumor treatment.This approval of the new indication provides a powerful alternative to chemotherapy for patients with EGFR mutant NSCLC after resistance to targeted drugs, and is expected to change the treatment pattern in this field and bring hope for the survival of more patients.

Click to read: http://sspacegen.com/newsinfo.aspx?newsID=477&CateID=109&wb=3

14/10/2025

What impact does HER2 status have on the treatment of gastric cancer? Traditionally, gastric cancer refers to an epithelial-derived malignant tumor that originates in the stomach. According to aggregated data from 2022, gastric cancer is the fifth most common malignant tumor in terms of both incidence and mortality worldwide, with an incidence rate of approximately 970,000 per year and a mortality rate of about 660,000 per year. Human epidermal growth factor receptor 2 (HER2) is a common and important target in gastric cancer. This article explores the gene characteristics that may affect tumor progression and treatment response in HER2-positive and HER2-negative gastric cancer patients, thereby providing new ideas and methods for personalized treatment of gastric cancer.

💡Click to read: http://sspacegen.com/newsinfo.aspx?newsID=476&CateID=109&wb=3

09/10/2025

Did you know? There is a "genetic cancer syndrome" that not only causes a family to successively suffer from colorectal cancer, but also makes women face a 60% risk of endometrial cancer and a 10% risk of ovarian cancer between the ages of 30 and 50. It is called Lynch syndrome, an often overlooked but potentially life-changing "invisible killer" that can be addressed through scientific means. What is Lynch syndrome?

Lynch syndrome is a hereditary cancer syndrome caused by mutations in mismatch repair genes (MMR), which leads to the failure of the DNA repair system, accumulation of cell mutations, and a sharply increased risk of cancer.
(1) Women need to be most vigilant: the risk of endometrial cancer (EC) is 40-60%, and the risk of ovarian cancer (OC) is 8-10%.
(2) Early onset of the disease: It occurs 10 to 20 years earlier than in the general population, and some may develop cancer as early as age 30.
(3) Family clustering: Several generations within a family may be affected, especially with colorectal cancer, endometrial cancer, and ovarian cancer.

Three sentences for every Lynch syndrome female.
（1）You are not destined to get cancer – scientific means can significantly reduce the risk.
(2) You are not alone in this fight - the genetic counseling clinic, gynecological oncology department, and psychological support are all by your side.
(3) You are not passively waiting - starting from today, actively monitor, actively consult, and actively make decisions.

29/09/2025

🎯MRD stands for Molecular Residual Disease testing, which refers to the small amount of cancer cells remaining in the body after cancer treatment. Traditional imaging or laboratory methods cannot detect it early, but through MRD liquid biopsy, cancer-derived molecular abnormalities can be identified, allowing for earlier intervention plans to be implemented.

🧬The main functions of MRD detection are prognosis prediction, recurrence risk assessment, and therapeutic efficacy monitoring. It is widely applied in various types of cancer, including lung cancer, colorectal cancer, breast cancer, esophageal cancer, liver cancer, gastric cancer, bladder cancer, and pancreatic cancer.

🔬SpaceGen now offers two technical routes. One is a fixed-panel test based on plasma ctDNA, which can detect 194 genes in four types of cancer including lung cancer, colorectal cancer, gastric cancer and liver cancer in one go. In addition, personalized panel customization can also be provided as needed.

📩 For the complete product catalog or to explore more cooperation opportunities, feel free to contact us at spacegen@ispacegen.com.

🌍 Welcome to visit the official website of SpaceGen for more information: sspacegen.com

, ,

28/09/2025

《Revisiting the Molecular Classification of Endometrial Cancer》

The TCGA molecular typing of endometrial cancer integrates genomic, transcriptomic, proteomic, gene copy number, and methylation data, classifying EC into four subtypes: POLE ultramutated (POLEmut), microsatellite instability-high (MSI-H), copy number low (CNL), and copy number high (CNH). Since then, many scholars have simplified the methodology and optimized the process of EC molecular typing, proposing the TransPORTEC and ProMisE molecular typing strategies. Molecular typing has gradually gained an increasingly important position. Nowadays, molecular typing has been recommended by domestic and international guidelines and consensus, and the new FIGO 2023 staging system has also incorporated molecular features .

Although molecular typing of endometrial cancer has been recommended by multiple guidelines and consensus, it is undeniable that there are still many problems with the current molecular typing. There are many blank areas and issues worth exploring in the clinical application stage, such as how molecular typing can guide the selection of surgical scope; whether immune and targeted drugs based on molecular typing results can be recommended as first-line options for fertility preservation or clinical adjuvant therapy, etc. With the continuous development of molecular biology technology and the conduct of prospective clinical research trials, the precise diagnosis and treatment of endometrial cancer are expected to be further improved.

Original Article Express：www.sspacegen.com

10/09/2025

Over the past 40 years, small cell lung cancer (SCLC) has been a clinical "hard nut to crack", with almost no options left after chemotherapy resistance.

Now, a major review in Nature Cancer brings six breakthrough directions, offering the first glimpse of the possibility of being besieged by "curative-level" therapies for this "incurable disease". SCLC has finally entered the "treatment explosion" era!

The treatment of SCLC is shifting from "laboratory to clinical" to "bedside back to laboratory" reverse translation: circulating clinical observations, deep omics, tissue banks and rapid autopsy results back to the laboratory to drive hypothesis validation and target discovery; while using surface omics, ADC/TCE new drugs, rational combination regimens, limiting phenotypic plasticity and epigenetic intervention to counter heterogeneity and resistance; moving the battle line forward through smoking cessation, early screening and circulating biomarkers; and solving the obstacles of age, comorbidities and economic accessibility in the real world to truly implement innovative therapies.

Original Article Express：www.sspacegen.com

Xiamen Spacegen Co., Ltd.

28/11/2025

26/11/2025

25/11/2025

21/11/2025

31/10/2025

31/10/2025

15/10/2025

14/10/2025

09/10/2025

29/09/2025

28/09/2025

10/09/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share